{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-23-001594","form_type":"8-K","ticker":"UFPT","cik":"0000914156","company_name":"UFP TECHNOLOGIES INC","filed_at":"2023-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.527039+00:00","generated_at":"2026-06-18T06:11:36.629633+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"UFP Technologies reports record 2022 revenue $353.8M, EPS $5.45 (+160% YoY)","bullets":["Full-year 2022 revenue $353.8M (+71.5% YoY); net income $41.8M ($5.45 diluted EPS) vs $15.9M ($2.09) in 2021.","Q4 2022 revenue $91.2M (+61.9% YoY); net income $8.5M ($1.10 diluted EPS) vs $3.2M ($0.42) in Q4 2021.","Medical market sales grew 116% to $286.2M for the year; acquisitions (DAS, Contech, Advant Medical) performed above expectations.","Organic base business grew 18.6% in 2022; adjusted operating income $44.5M vs $21.6M in 2021.","Ended year with ~$55M debt; management bullish on synergies and new investments."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-23-001594","json":"https://secwatch.observer/filing/0001171843-23-001594.json","markdown":"https://secwatch.observer/filing/0001171843-23-001594.md","text":"https://secwatch.observer/filing/0001171843-23-001594.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/914156/000117184323001594/0001171843-23-001594-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/914156/000117184323001594/f8k_031023.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T06:11:36.629633+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4192c442b3c3d9f843bd281b6003528c4bb429dd","claim":"UFP TECHNOLOGIES INC reported its fourth quarter ended December 31, 2022 results: revenue $91.2 million, net income $8.5 million, EPS $1.10 per diluted common share.","evidence_excerpt":"For its fourth quarter ended December 31, 2022, the Company reported net income of $8.5 million or $1.10 per diluted common share outstanding, compared to $3.2 million or $0.42 per diluted common share outstanding in the same period of 2021. Sales for the fourth quarter 2022 were $91.2 million versus 2021 fourth quarter sales of $56.3 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914156/000117184323001594/0001171843-23-001594-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$91.2 million"},{"label":"Net income","value":"$8.5 million"},{"label":"EPS","value":"$1.10 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"f923e910ab08d825a6fbd3e9e83db3f9d8d9550d","claim":"UFP TECHNOLOGIES INC reported its year ended December 31, 2022 results: revenue $353.8 million, net income $41.8 million, EPS $5.45 per diluted common share.","evidence_excerpt":"UFP Technologies, Inc. (Nasdaq: UFPT), a designer and custom manufacturer of engineered solutions primarily for the medical market, today reported net income of $41.8 million or $5.45 per diluted common share outstanding for its year ended December 31, 2022, compared to net income of $15.9 million or $2.09 per diluted common share outstanding for 2021. Net Sales for 2022 were $353.8 million compared to 2021 sales of $206.3 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/914156/000117184323001594/0001171843-23-001594-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"its year ended December 31, 2022"},{"label":"Revenue","value":"$353.8 million"},{"label":"Net income","value":"$41.8 million"},{"label":"EPS","value":"$5.45 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}